Paper - WANFANG MED ONLINE

You Position: Home > Paper

Consensus on clinical diagnosis and treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (2022 edition)

( views:370, downloads:21 )

Author:: No author available

Journal Title:: Chinese Journal of Oncology

Issue:: 12

DOI:: 10.3760/cma.j.cn112152-20220914-00623

Key Word:: 乳腺肿瘤;人表皮生长因子受体2;低表达;抗体偶联药物;Breast neoplasms;Human epidermal growth factor receptor 2;Low expression;Antibody-drug conjugate

Abstract： The treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (HER-2) has become a focused area in recent years. With the proved therapeutic effect of antibody-drug conjugate on breast cancer patients with HER-2 low expression, HER-2-low expression may become a new subtype for targeted therapies of breast cancer. Standardized diagnosis and treatment are the foundation to guarantee efficacy. In order to improve the standardization of clinical diagnosis and treatment of HER-2-low breast cancer, the Consensus Expert Committee has summarized the latest domestic and global clinical data and the key relevant publications in recent years. We have combined them with clinical experience of pathologists and oncologists, had a deep discussion within the committee, and developed the consensus. We believe this consensus could help clinicians improve the understanding about HER-2-low breast cancer, promote the accuracy of decision-making and achieve the ultimate goal of prolonging the overall survival and improving the quality of life of patients.

Reference

[1]孟祥颖,宋三泰.乳腺癌骨转移药物治疗的疗效评价及分类处理[J].2017,(3).
[2]闫敏,宋三泰,江泽飞,等.乳腺癌骨转移内分泌治疗与化疗的对比研究[J].2004,(3).
[3]Hu, Xi-Chun,Zhang, Jian,Xu, Bing-He,etc.Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial[J].2015,16(4).
[4]Stefanopoulou, Evgenia,Grunfeld, Elizabeth Alice.Mind-body interventions for vasomotor symptoms in healthy menopausal women and breast cancer survivors. A systematic review[J].2017,38(3).
[5]Kathleen I. Pritchard,Howard A. Burris,III,etc.Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2[J].2013,13(6).
[6]Dan,Shan,Li,Zou,Xijiao,Liu,etc.Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis.[J].2019.
[7]Gucalp, Ayca,Traina, Tiffany A.,Eisner, Joel R.,etc.Male breast cancer: a disease distinct from female breast cancer[J].2019,173(1).
[8]Cardoso, Fatima,Cruz, Felipe Melo,Lin, Chinjune,etc.Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial[J].2018,4(7).
[9]Gelmon, Karen A.,Boyle, Frances M.,Kaufman, Bella,etc.Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31[J].2015,33(14).
[10]James P. Neifeld,Frank Meyskens,Douglass C. Tormey,etc.The role of orchiectomy in the management of advanced male breast cancer[J].1976,37(2).
[11]Shui, Ruohong,Liang, Xizi,Li, Xiaomei,etc.Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers[J].2020,20(1).
[12]Soran Atilla,Dogan Lutfi,Isik Arda,etc.The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study[J].2021,28(9).
[13]Ruth, Farrell.ACOG Committee Opinion No. 659: The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer.[J].2016.
[14]Johns, Claire,Claire Johns,Seav, Susan M.,etc.Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions[J].2016,156(3).
[15]Cao Wei,Chen Hong-Da,Yu Yi-Wen,etc.Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J].2021,(7).
[16]Ercolani C,Papaldo P,Fabi A,etc.HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.[J].2011,17(7).
[17]Cardoso,F.,Costa,A.,Norton,L.,etc.ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)[J].2014,23(5).
[18]VanDulken,E.J.,Hunter,M.S.,Stuiver,M.M.,etc.Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: Results of a randomized, controlled, multicenter trial[J].2012,30(33).
[19]Costelloe CM,Madewell J,Hamaoka T.Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer.[J].2010,102(4).
[20]Hayashi H,Yoshimoto N,Kimura M.A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment.[J].2009,16(2).
[21]Balabanovic,J.A.,Hellier,J.,Grunfeld,E.A.,etc.Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): A randomised controlled trial[J].2012,13(3).
[22]Jassem J,Maenpa J,Dobaczewska D,etc.Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.[J].2008,100(7).
[23]Donders G.,Bellen G.,Neven P.,etc.Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors[J].2015,34(10).
[24]Pestalozzi,B.C.,Holmes,E.,deAzambuja,E.,etc.CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: A retrospective substudy of the HERA trial (BIG 1-01)[J].2013,14(3).
[25]Sook-Bin, Woo,John W, Hellstein,John R, Kalmar.Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.[J].2006,144(10).
[26].Visceral Crisis Means Short Survival Among Patients With Luminal A Metastatic Breast Cancer: A Retrospective Cohort Study[J].2017,8(4).
[27]M E, Costanza,D, Berry,I C, Henderson,etc.Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).[J].1995,1(7).
[28]Laura, Ottini,Carlo, Capalbo,Piera, Rizzolo,etc.HER2-positive male breast cancer: an update.[J].2010,2.
[29]Peccatori, Fedro,Corneliussen-James, Dian,Cardoso, Maria-Joao,etc.Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015)[J].2018,39.
[30]Ian M, Lahart,George S, Metsios,Alan M, Nevill,etc.Physical activity for women with breast cancer after adjuvant therapy.[J].2018,1(Spec ).
[31]Giotta, Francesco,Acito, Luigi,Candeloro, Giampiero,etc.Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes[J].2016,21(11).
[32]Zongbi,Yi,Binliang,Liu,Xiaoying,Sun,etc.Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers.[J].2020,52.
[33].Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study[J].2013,14(1).
[34]Jenny Chang,Gary M. Clark,D. Craig Allred,etc.Survival of patients with metastatic breast carcinoma: Importance of prognostic markers of the primary tumor[J].2003,97(3).
[35]Kim, Sung-Bae,Dent, Rebecca,Im, Seock-Ah,etc.Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J].2017,18(10).
[36]Eakle, Janice,Cortes, Javier,Winer, Eric,etc.Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer[J].2018,36(9).
[37]Aleskandarany MA,Rakha EA,Ahmed MA,etc.PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.[J].2010,122(1).
[38]Montemurro, F.,Delaloge, S.,Barrios, C. H.,etc.Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial[J].2020,31(10).
[39]Ramaswami, Ramya,Villarreal, Marcos Daniel,Pitta, Dina Marie,etc.Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis[J].2015,152(2).
[40]Dieras, Veronique,Han, Hyo S.,Kaufman, Bella,etc.Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial[J].2020,21(10).
[41]Lutz ST,Roberts CC,Olson JJ,etc.ACR appropriateness criteria on metastatic bone disease.[J].2010,7(6).
[42]Tutt, Andrew,Tovey, Holly,Cheang, Maggie Chon U.,etc.Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial[J].2018,24(5).
[43]Janni, Wolfgang,Alba, Emilio,Bachelot, Thomas,etc.First-line ribociclib plus letrozole in postmenopausal women with HR+, HER2-advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial[J].2018,169(3).
[44]Gonzalez-Angulo AM,Morales-Vasquez F,Hortobagyi GN.Overview of resistance to systemic therapy in patients with breast cancer.[J].2007,608(0).
[45]Hainsworth JD,Spigel DR,Yardley DA,etc.Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer.[J].2009,9(3).
[46]Jiang, Zefei,Li, Wei,Hu, Xichun,etc.Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial[J].2019,20(6).
[47]Cardoso,F.,van'tVeer,L.,Fallowfield,L.,etc.1st International consensus guidelines for advanced breast cancer (ABC 1)[J].2012,21(3).
[48]Heather B. Neuman,Mary Morrogh,Mithat Gonen,etc.Stage IV breast cancer in the era of targeted therapy[J].2010,116(5).
[49]Robson, Mark,Im, Seock-Ah,Senkus, Elzbieta,etc.Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation[J].2017,377(6).
[50]Rugo H. S.,Finn R. S.,Diéras V.,etc.Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up[J].2019,174(3).
[51]Eiermann W,Lindsay MA,Valero V,etc.Adjuvant trastuzumab in HER2-positive breast cancer.[J].2011,365(14).
[52]T M, Behr,M, Béhé,B, W?rmann.Trastuzumab and breast cancer.[J].2001,345(13).
[53]Bardia, A.,Mayer, I. A.,Vahdat, L. T.,etc.Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer[J].2019,380(8).
[54]Irene, Karam,Sarah, Hamilton,Alan, Nichol,etc.Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras.[J].2013,8.
[55]Azad, Gurdip K.,Goh, Vicky,Cook, Gary J. R..Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment[J].2016,57(Suppl.1).
[56]边莉,徐兵河,邸立军,等.重组抗HER2人源化单克隆抗体联合长春瑞滨治疗HER2阳性转移性乳腺癌随机对照Ⅲ期临床研究[J].2020,(30).
[57]Stephen Johnston,Miguel Martin,Angelo Di Leo,etc.MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer[J].2019,5(1).
[58]国家肿瘤质控中心乳腺癌专家委员会,北京乳腺病防治学会健康管理专业委员会.中国乳腺癌随诊随访与健康管理指南（2022版）[J].2022,44(1).
[59]Rudolf, Weide,Stefan, Feiten,Vera, Friesenhahn,etc.Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors.[J].2014,3.
[60]Yardley,D.A.,Noguchi,S.,Pritchard,K.I.,etc.Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis[J].2013,30(10).
[61]Matthew H F, Wong,Martin R, Stockler,Nick, Pavlakis.Bisphosphonates and other bone agents for breast cancer.[J].2012.
[62]Yimeng Chen,Yin Guan,Jiayu Wang,etc.Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China[J].2020,147(12).
[63]R A,Patchell,P A,Tibbs,W F,Regine,etc.Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial.[J].1998,280(17).
[64]Sledge, George W.,Toi, Masakazu,Neven, Patrick,etc.The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2 A Randomized Clinical Trial[J].2020,6(1).
[65]Ru,Wang,Yayun,Zhu,Xiaoxu,Liu,etc.The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer.[J].2019,19(1).
[66]Kaufman B,Mackey JR,Clemens MR,etc.Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.[J].2009,27(33).
[67]Carlotta,Costa,Ye,Wang,Amy,Ly,etc.PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer.[J].2020,10(1).
[68]Anton A,Extra JM,Kennedy J,etc.Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.[J].2005,23(19).
[69]Roberto A,Leon-Ferre,Paul J,Novotny,Eric G,Wolfe,etc.Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603).[J].2020,4(1).
[70]Mia Fahlen,Tommy Forner,Hemming Johansson,etc.Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial[J].2013,49(1).
[71]Maurizio Serati,Giorgio Bogani,Maria Carmela Di Dedda,etc.A comparison between vaginal estrogen and vaginal hyaluronic for the treatment of dyspareunia in women using hormonal contraceptive[J].2015,191.
[72]Robertson, John F. R.,Bondarenko, Igor M.,Trishkina, Ekaterina,etc.Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial[J].2016,388(10063).
[73]Modi, Shanu,Saura, Cristina,Yamashita, Toshinari,etc.Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer[J].2020,382(7).
[74]Origoni, M.,Cimmino, C.,Carminati, G.,etc.Postmenopausal vulvovaginal atrophy (VVA) is positively improved by topical hyaluronic acid application. A prospective, observational study[J].2016,20(20).
[75]Mazzarello, Sasha,Hutton, Brian,Ng, Terry,etc.Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials[J].2015,152(1).
[76]Cheema, Puneet,Brufsky, Adam,Telli, Melinda,etc.Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE[J].2018,36(16).
[77]Carmona-Bayonas A.Potential benefit of maintenance trastuzumab and anastrozole therapy in male advanced breast cancer.[J].2007,16(3).
[78]Eisenhauer EA,Therasse P,Bogaerts J,etc.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).[J].2009,45(2).
[79]Johnston S,Pippen J Jr,Pivot X,etc.Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.[J].2009,27(33).
[80]Wedam, Suparna,Fashoyin-Aje, Lola,Bloomquist, Erik,etc.FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer[J].2020,26(6).
[81]Turner, N. C.,Slamon, D. J.,Ro, J.,etc.Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer[J].2018,379(20).
[82]Sunil Verma,David Miles,Luca Gianni,etc.Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer[J].2012,367(19).
[83]Pivot, Xavier,Manikhas, Alexey,Zurawski, Bogdan,etc.CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer[J].2015,33(14).
[84]Shapiro, Charles L.,Moriarty, James P.,Dusetzina, Stacie,etc.Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance)[J].2017,35(35).
[85]Bardia, A.,Hurvitz, S. A.,Tolaney, S. M.,etc.Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer[J].2021,384(16).
[86]Hortobagyi, G. N.,Stemmer, S. M.,Burris, H. A.,etc.Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer[J].2018,29(7).
[87]Litton, Jennifer K.,Rugo, Hope S.,Ettl, Johannes,etc.Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation[J].2018,379(8).
[88]Amadori D,Stockler M,Wilcken N,etc.Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials.[J].2011,29(16).
[89]Domschke,C.,Schuetz,F..Side effects of bone-targeted therapies in advanced breast cancer[J].2014,9(5).
[90]Slamon, Dennis J.,Neven, Patrick,Chia, Stephen,etc.Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer[J].2020,382(6).
[91]Turner, N. C.,Finn, R. S.,Martin, M.,etc.Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases[J].2018,29(3).
[92]Innominato, Pasquale F.,Lim, Andrew S.,Palesh, Oxana,etc.The effect of melatonin on sleep and quality of life in patients with advanced breast cancer[J].2016,24(3).
[93]Murthy, R. K.,Loi, S.,Okines, A.,etc.Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer[J].2020,382(7).
[94].Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.[J].2009,10(11).
[95]Shaveta Vinayak,Sara M. Tolaney,Lee Schwartzberg,etc.Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer[J].2019,5(8).
[96]Vigneau FD,Lai P,Sloan AE,etc.Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.[J].2004,22(14).
[97]S. Buchholz,M. Mögele,A. Lintermans,etc.Vaginal estriol–lactobacilli combination and quality of life in endocrine-treated breast cancer[J].2015,18(2).
[98]Sinacki M,Badzio A,Welnicka Jaskiewicz M,etc.Pattern of care in locally advanced breast cancer: focus on local therapy.[J].2011,20(2).
[99]Sheri J. Hartman,Sandahl H. Nelson,Emily Myers,etc.Randomized controlled trial of increasing physical activity on objectively measured and self‐reported cognitive functioning among breast cancer survivors: The memory & motion study[J].2018,124(1).
[100]Losurdo, Agnese,Rota, Selene,Gullo, Giuseppe,etc.Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: A review of the literature[J].2017,113.
[101]Vicente Valero,Aman U. Buzdar,Gabriel N. Hortobagyi.Locally Advanced Breast Cancer[J].1996,1(1-2).
[102]Mehta,R.S.,Barlow,W.E.,Albain,K.S.,etc.Combination anastrozole and fulvestrant in metastatic breast cancer[J].2012,367(5).
[103]Xu Binghe,Li Wei,Zhang Qingyuan,etc.Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study[J].2020,182(3).
[104].Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study[J].2020,21(4).
[105]O’Brien Neil A.,McDermott Martina S. J.,Conklin Dylan,etc.Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer[J].2020,22(1).
[106]Andersson M,Wist E,Moller S,etc.Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.[J].2011,29(3).
[107]José R. Rossari,Otto Metzger-Filho,Marianne Paesmans,etc.Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence[J].2012,2012.
[108]Sari E,Arslan C,Aksoy S,etc.Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature.[J].2011,15(1).
[109]N, Wilcken,J, Hornbuckle,D, Ghersi.Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer.[J].2003,(2).
[110]Caruso, Salvatore,Cianci, Stefano,Amore, Francesca F.,etc.Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel[J].2016,23(1).
[111]Reena, George,Jenifer, Jeba,Govindraj, Ramkumar,etc.Interventions for the treatment of metastatic extradural spinal cord compression in adults.[J].2008,(4).
[112]国家卫生计生委合理用药专家委员会.乳腺癌合理用药指南[M].2019.
[113]G N, Hortobagyi.Multidisciplinary management of advanced primary and metastatic breast cancer.[J].1994,74(1 Suppl).
[114]Schmid, P.,Adams, S.,Rugo, H. S.,etc.Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer[J].2018,379(22).
[115]Parnes H.L..Phase III Study of Cyclophosphamide, Doxorubicin, and Fluorouracil (CAF) Plus Leucovorin Versus CAF for Metastatic Breast Cancer: Cancer and Leukemia Group B 9140[J].2003.
[116]Eubank WB,Mankoff D,Bhattacharya M,etc.Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer.[J].2004,183(2).
[117]Mayer, Sebastian,Iborra, Severine,Grimm, Donata,etc.Sexual activity and quality of life in patients after treatment for breast and ovarian cancer[J].2019,299(1).
[118]Stute,P..Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief?[J].2013,288(6).
[119]Chen,W.Y.,Giobbie-Hurder,A.,Gantman,K.,etc.A randomized, placebo-controlled trial of melatonin on breast cancer survivors: Impact on sleep, mood, and hot flashes[J].2014,145(2).
[120]Bachelot,T.,Ray-Coquard,I.,Legouffe,E.,etc.Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study[J].2012,30(22).
[121]Verma, Sunil,O'Shaughnessy, Joyce,Burris, Howard A.,etc.Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib plus letrozole: results from MONALEESA-2[J].2018,170(3).
[122]Ding,X.Y.,Cai,R.G.,Yuan,P.,etc.Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer[J].2013,24(5).
[123]Gunter, von Minckwitz,Andreas, du Bois,Marcus, Schmidt,etc.Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.[J].2009,27.